Detailed explanation of the advantages of dual target therapy with tirzepatide, and what are the advantages of a stronger weight loss drug after semaglutide

Detailed explanation of the advantages of dual target therapy with tirzepatide, and what are the advantages of a stronger weight loss drug after semaglutide

tirzepatide is a molecule modified based on the GIP sequence, which increases the activity of GLP-1. Its GIP activity is approximately 10 times that of GLP-1. This dual target drug that combines GLP-1 and GIP exhibits significant therapeutic effects through their complementary and synergistic effects.

Firstly, GLP-1 may cause central nervous system side effects such as nausea and vomiting. GIP can alleviate these discomfort symptoms while reducing appetite, thereby offsetting the side effects of GLP-1 to some extent.

Secondly, the roles of GIP and GLP-1 in the pancreas are also different. GIP can not only regulate glucose metabolism, but also regulate lipid metabolism, which is very important for controlling blood sugar and blood lipids. In addition, GIP has a high expression level in subcutaneous adipose tissue, which means it plays an important role in fat metabolism. GIP helps promote the rebalancing and redistribution of body fat, improve the storage capacity of adipose tissue, and reduce abnormal fat accumulation. This is a significant advantage of dual target drugs containing GIP compared to single target drugs.

Through this innovative molecular design, tirzepatide not only improves the therapeutic effect, but also reduces possible side effects, providing a new treatment option for diabetes patients

In the field of metabolic disease research, following GLP-1 (glucagon like peptide-1) single target drugs, GLP-1/GIP (glucose dependent insulinotropic polypeptide) dual target drugs have shown potential in reducing blood sugar and weight due to their multiple effects in the pancreas, adipose tissue, and central nervous system, making them a hot research topic. Clinical data continuously confirms that GLP-1/GIP dual receptor agonists can exert synergistic or complementary effects by activating GLP-1 and GIP receptors, thereby improving blood glucose control and weight loss.

The effects of GLP-1 and GIP are mainly divided into two categories: one is their effects inside the pancreas, and the other is their effects outside the pancreas. When these hormones bind to their corresponding receptors, they exert biological effects. GLP-1 and GIP receptors are not only expressed in pancreatic islet cells, but also distributed in the central nervous system, while adipocytes express GIP receptors. After GLP-1 and GIP bind to receptors, they achieve comprehensive regulation of energy metabolism balance through synergistic or complementary mechanisms, including energy intake, storage, and metabolism. The latest research progress shows that the combination of GLP-1 or GIP can significantly enhance insulin secretion, inhibit glucagon response, reduce energy intake, and improve insulin sensitivity compared to using GLP-1 or GIP alone. These findings have promoted the research and development of GLP-1/GIP dual receptor agonists in the treatment of metabolic diseases such as diabetes and obesity.